Duality Biologics (DualityBio), one of the Chinese firms making waves on the world antibody-drug conjugate stage since 2022, has revealed four new domestic antibody partnerships that put the fledgling biotech on a course to becoming an ADC bellwether in the country.
Key Takeaways
-
China's DualityBio reveals details of new domestic antibody partnerships that are helping it accelerate the development of four clinical-stage ADCs.
-
Those with WuXi Biologics and Harbour BioMed are focused on B7-H3-targeting DB-1311 and B7-H4-targeting DB-1312, respectively
The disclosures came as DualityBio on 26 August filed for an initial public offering on the Hong Kong Stock Exchange, on the back of a fully diluted valuation of $270m
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?